The interim data strongly supports INBRX-106's potential as a best-in-class OX40 agonist, with a clear efficacy signal over PD-1 monotherapy. Watch for PFS data in 4Q 2026 and Phase 3 initiation in 3Q 2026 as key catalysts. The expansion into NSCLC (perioperative study this quarter, 1L metastatic in 2027) represents a significant value driver. Monitor for any safety signals as the trial matures.
Price Chart
Executive Summary
Inhibrx reported positive interim Phase 2 data for INBRX-106 in first-line HNSCC, showing a 44.0% confirmed objective response rate (cORR) in the combination arm versus 21.4% for pembrolizumab alone, with 3 complete responses in the combo arm versus none in the control. The company plans to initiate a Phase 3 study in 3Q 2026 and expand into perioperative NSCLC. This is a material clinical catalyst that validates the OX40 agonist mechanism and opens a large addressable market opportunity.
Key Facts
- INBRX-106 + pembrolizumab achieved 44.0% cORR vs 21.4% for pembrolizumab alone (22.6% absolute improvement) in evaluable population of 53 patients
- 3 complete responses observed in combination arm; zero in control arm
- Up to 15-fold increase in peripheral CD8+ and CD4+ T-cell proliferation in combo arm vs up to 2.5-fold in control
- No treatment-related deaths reported in either arm; safety profile manageable
- Company estimates total addressable market of approximately $50 billion across all checkpoint inhibitor indications
- Phase 3 HexAgon study initiation planned for 3Q 2026; PFS data expected 4Q 2026
- Perioperative NSCLC study to begin later this quarter; front-line metastatic NSCLC studies expected to begin in 2027
- Cash and cash equivalents of $124.2M as of 12/31/2025
Financial Impact
Potential multi-billion dollar market opportunity if INBRX-106 expands across checkpoint inhibitor indications; company estimates $50B total addressable market
Risk Factors
- Data is preliminary from only 53 of 68 enrolled patients; final results may differ
- PFS data not yet available; ORR improvement may not translate to survival benefit
- Competitive landscape includes other OX40 agonists and combination immunotherapies
- Regulatory and commercial execution risks for a clinical-stage biotech
- Cash runway of $124.2M may require additional financing to fund expanded clinical program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0002007919-26-000020 |
| Exhibit: exhibit991-pressreleasemay.htm | 0002007919-26-000020 |
| Document: inhibrxpresentation_may2.htm | 0002007919-26-000020 |
| Document: 0002007919-26-000020-index-headers.html | 0002007919-26-000020 |
| Document: 0002007919-26-000020-index.html | 0002007919-26-000020 |
| Document: 0002007919-26-000020.txt | 0002007919-26-000020 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | Insider Buy | $90.50 | awaiting T+60 | — | $95.66 (+5.70%) |
Sep 28, 2026 28d ago | Insider Cluster | $104.83 | awaiting T+60 | — | $95.66 (−8.75%) |
Sep 17, 2026 5w ago | Insider Cluster | $109.35 | awaiting T+60 | — | $95.66 (−12.52%) |
Sep 15, 2026 5w ago | Insider Cluster | $101.77 | awaiting T+60 | — | $95.66 (−6.00%) |
Sep 15, 2026 6w ago | 144 | $101.77 | awaiting T+60 | — | $95.66 (−6.00%) |
Sep 14, 2026 6w ago | 144 | $105.61 | awaiting T+60 | — | $95.66 (−9.42%) |
Sep 11, 2026 6w ago | 144 | $109.27 | awaiting T+60 | — | $95.66 (−12.46%) |
Sep 10, 2026 6w ago | Insider Cluster | $109.27 | awaiting T+60 | — | $95.66 (−12.46%) |
Sep 8, 2026 6w ago | Insider Cluster | $112.86 | awaiting T+60 | — | $95.66 (−15.24%) |
Sep 8, 2026 7w ago | Insider Buy | $112.86 | awaiting T+60 | — | $95.66 (−15.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers